Preclinical Evaluation of an Al 18 F-Radiolabeled Bicyclic Peptide Targeting Nectin-4
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.4c00858 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Xiaojiang Duan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China. Hauptthemen laut MEDLINE: Cell Adhesion Molecules, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China, National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Precisely assessing nectin-4 expression in tumors is important in identifying patients who may benefit from nectin-4-targeted therapies. In our previous work, we developed a bicyclic peptide-based nectin-4-targeting radiotracer 68Ga-N188 and validated its nectin-4 detection efficacy. However, the relatively short half-life and low positron emission rate of 68Ga limit its further application. In this study, we constructed three novel nectin-4-targeting ligands N230-232 based on a bicyclic peptide structure and labeled with radionuclide 18F, which has a longer half-life and a higher positron emission rate, for PET imaging. Micro-PET/CT imaging-based screening showed that Al18F-N231 had the best imaging contrast with a tumor-to-muscle ratio of 10.97 ± 2.39. Further characterization demonstrated that ligand N231 had a high affinity to nectin-4 with a Kd of 4.29 nM, and Al18F-N231 had a good stability and safety profile in vivo. Biodistribution studies validated the specific binding of Al18F-N231 to nectin-4 in vivo, with tumor uptake in the nectin-4+ SW780 tumor group being 1.45- and 3.75-fold higher than that in the nectin-4- 5637 tumor group and blocking group, respectively. Based on the results of this work, Al18F-N231 has promising capability for noninvasive nectin-4 detection in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
- Department of Nuclear Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
- Department of Central Laboratory, Peking University First Hospital, Beijing 100034, China.
- Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration, NMPA), Beijing 100142, China.
- Institute of Medical Technology, Peking University Health Science Center, Beijing 100191, China.
- International Cancer Institute, Peking University Health Science Center, Beijing 100191, China.
ORCID-Profile: Xing Yang
Förderung
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Duan, X., Zhang, Z., Xu, H., Zhang, J., Yan, Y., & Yang, X. (2025). Preclinical Evaluation of an Al 18 F-Radiolabeled Bicyclic Peptide Targeting Nectin-4. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00858
Vancouver
Duan X, Zhang Z, Xu H, Zhang J, Yan Y, Yang X. Preclinical Evaluation of an Al 18 F-Radiolabeled Bicyclic Peptide Targeting Nectin-4. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c00858
BibTeX
@article{Duan2025,
author = {Duan, Xiaojiang and Zhang, Zhuochen and Xu, Hongchuang and Zhang, Jingming and Yan, Yue and Yang, Xing},
title = {Preclinical Evaluation of an Al 18 F-Radiolabeled Bicyclic Peptide Targeting Nectin-4},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.4c00858}
}
EUVIMED